Literature DB >> 32914327

Intestinal occlusion by gynecological cancers treated by percutaneous endoscopic gastrostomy and lanreotide: an Aviano National Cancer Institute experience.

Martina Budel1, Luca Martella2, Laura Zambon1, Isabella Morson1, Giorgio Giorda2, Renato Cannizzaro3,4.   

Abstract

The Commentary reports on our experience in Centro di Riferimento Oncologico IRCCS Aviano about the integrated and combined treatment with percutaneous endoscopic gastrostomy and lanreotide in patients with bowel obstructions by ovarian cancer and peritoneal carcinomatosis. We treated patients with gynecological cancers and bowel obstruction with percutaneous endoscopic gastrostomy and, when patients were partially responsive, with lanreotide. We registered a constant overall benefit for the quality of life and for the control of symptoms, which is very important especially during the home care follow-up of terminal patients.

Entities:  

Keywords:  Gynecological cancers; Lanreotide; Percutaneous endoscopic gastrostomy

Year:  2020        PMID: 32914327      PMCID: PMC7767898          DOI: 10.1007/s00520-020-05745-x

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  11 in total

1.  Palliative treatment of upper intestinal obstruction by gynecological malignancy: the usefulness of percutaneous endoscopic gastrostomy.

Authors:  E Campagnutta; R Cannizzaro; A Gallo; A Zarrelli; M Valentini; M De Cicco; C Scarabelli
Journal:  Gynecol Oncol       Date:  1996-07       Impact factor: 5.482

2.  Percutaneous endoscopic gastrostomy-20 years later: a historical perspective.

Authors:  M W Gauderer
Journal:  J Pediatr Surg       Date:  2001-01       Impact factor: 2.545

3.  Percutaneous endoscopic gastrostomy tube placement in patients with malignant bowel obstruction due to ovarian carcinoma.

Authors:  Bhavana Pothuri; Michelle Montemarano; Melissa Gerardi; Moshe Shike; Leah Ben-Porat; Paul Sabbatini; Richard R Barakat
Journal:  Gynecol Oncol       Date:  2005-02       Impact factor: 5.482

4.  Percutaneous endoscopic gastrostomy/jejunostomy (PEG/PEJ) for decompression in the upper gastrointestinal tract. Initial experience with palliative treatment of gastrointestinal obstruction in terminally ill patients with advanced carcinomas.

Authors:  H Scheidbach; T Horbach; H Groitl; W Hohenberger
Journal:  Surg Endosc       Date:  1999-11       Impact factor: 4.584

5.  Cancer statistics, 2020.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2020-01-08       Impact factor: 508.702

6.  Octreotide in the management of bowel obstruction in terminal ovarian cancer.

Authors:  G Mangili; M Franchi; A Mariani; F Zanaboni; E Rabaiotti; L Frigerio; P F Bolis; A Ferrari
Journal:  Gynecol Oncol       Date:  1996-06       Impact factor: 5.482

7.  Percutaneous endoscopic gastrostomy as a decompressive technique in bowel obstruction due to abdominal carcinomatosis.

Authors:  R Cannizzaro; F Bortoluzzi; M Valentini; C Scarabelli; E Campagnutta; M Sozzi; M Fornasarig; M Poletti
Journal:  Endoscopy       Date:  1995-05       Impact factor: 10.093

Review 8.  [Percutaneous endoscopic gastrostomy (PEG) in upper gastrointestinal tract occlusion in gynecologic oncology].

Authors:  E Campagnutta; R Cannizzaro; M De Cicco; G De Piero; G Giorda; F Sopracordevole; A Parin; C Scarabelli
Journal:  Minerva Ginecol       Date:  1998 Jul-Aug

9.  Symptomatic treatment with lanreotide microparticles in inoperable bowel obstruction resulting from peritoneal carcinomatosis: a randomized, double-blind, placebo-controlled phase III study.

Authors:  Pascale Mariani; Joëlle Blumberg; Alain Landau; Daniela Lebrun-Jezekova; Estelle Botton; Olivier Beatrix; Didier Mayeur; Robert Herve; Pascal Maisonobe; Laure Chauvenet
Journal:  J Clin Oncol       Date:  2012-10-29       Impact factor: 44.544

10.  Decompressive percutaneous endoscopic gastrostomy in advanced cancer patients with small-bowel obstruction is feasible and effective: a large prospective study.

Authors:  Elena Zucchi; Mara Fornasarig; Luca Martella; Stefania Maiero; Emilio Lucia; Eugenio Borsatti; Luca Balestreri; Giorgio Giorda; Maria Antonietta Annunziata; Renato Cannizzaro
Journal:  Support Care Cancer       Date:  2016-02-02       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.